Navigation Links
ULURU Inc. Reports Second Quarter 2010 Financial Results

ADDISON, Texas, Aug. 17 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced its financial results for the second quarter ended June 30, 2010.

For the second quarter of 2010, the Company reported a net loss of $2.2 million, or $0.03 per share, compared with a net loss of $2.9 million, or $0.04 per share, for the same period last year.  For the six months ended June 30, 2010, the Company reported a net loss of $3.5 million, or $0.04 per share, compared with a net loss of $6.0 million, or $0.09 per share, for the same period last year.  At June 30, 2010, the Company held cash and cash equivalents of $1.7 million, compared with $1.9 million at December 31, 2009.

Commenting on the financial results Kerry P. Gray, President and CEO, stated, "In addition to the report of achievements during the second quarter, significant progress has been made in the marketing of Altrazeal® in the U.S.  Both internal and external sales forces have been expanded and Altrazeal® marketing has been focused on the major wound categories where we have developed strong clinical support, including diabetic foot ulcers, venous leg ulcers, and home healthcare.  We believe that benefits are now starting to be derived from our revised marketing strategy which will begin to be recognized in the second half of 2010.  We continue to evaluate ways to expand our sales marketing capabilities, including possible corporate collaborations.  The clinical data supporting Altrazeal® continues to demonstrate clinical advantages and cost benefits that clearly differentiate Altrazeal® from competitive products."

Mr. Gray added, "We were pleased to report the achievement of two important milestones during the second quarter, the Altrazeal® licensing agreement for China and the granting of the CE Mark.  With the granting of the CE Mark, the Altrazeal® asset becomes more valuable as the product is now approved for marketing throughout Europe and other markets.  We continue to evaluate potential partnerships and the Chinese agreement is the first of what we believe will be a series of agreements to market Altrazeal® worldwide.  The Chinese agreement, the divestiture of Zindaclin®, and potential additional Altrazeal® agreements will provide the company with additional liquidity in the near term."

Operating ResultsRevenues

Revenue for the second quarter of 2010 was $232,000, compared to $136,000 for the second quarter of 2009.  The increase of $96,000 in revenue was due primarily to an increase of $100,000 in licensing fees related to the achievement of a milestone relating to Zindaclin®.

Research and Development

Research and development expenses for the second quarter of 2010 were $367,000, including $41,000 in share-based compensation, compared to $854,000, including $213,000 in share-based compensation, for the second quarter of 2009.  The decrease of $487,000 in research and development expenses continues to reflect the impact of the Company's restructured business plan which contributed to decreases in scientific personnel costs of $356,000, regulatory consulting expenses of $128,000, and clinical testing expenses for our wound care technologies of $66,000.  These expense decreases were partially offset by an increase in regulatory fees of $37,000 and direct research costs of $33,000.

Selling, General and Administrative

Selling, general and administrative expenses for the second quarter of 2010 were $0.9 million, including $47,000 in share-based compensation, compared to $1.8 million, including $279,000 in share-based compensation, for the second quarter of 2009.  The decrease of $913,000 in selling, general and administrative expenses continues to reflect the impact of the Company's restructured business plan which contributed to reduced costs associated with our sales and marketing efforts of $579,000 due to lower head count and marketing expenses, a decrease of $297,000 in administrative compensation, lower consulting fees of $41,000, a decrease of $8,000 in corporate travel expenses, and lower legal fees of $191,000.  These expense decreases were partially offset by an increase in director fees of $79,000, commissions totalling $30,000 related to the Chinese licensing agreement, costs of $40,000 associated with our annual meeting of shareholders, increased public relation expenses of $36,000, and legal fees related to our patents of $26,000.Other income and Other expenses

Interest and miscellaneous income for the second quarter of 2010 was $594 as compared to $21,066 for the second quarter of 2009.  The decrease of $20,000 is attributable to a decrease in interest income due to lower cash balances and interest yields in 2010.

Interest expense totalled $8,500 for the three months ended June 30, 2010 and consisted of interest costs associated with regulatory fees.  There was no interest expense for the three months ended June 30, 2009.

Loss on sale of intangible asset totalled $857,839 for the three months ended June 30, 2010 and resulted from the divestiture of our Zindaclin® intangible asset.  This loss reflects a conservative position in respect to future milestone payments where only guaranteed payments are reflected in the valuation of the divestiture proceeds.  There was no intangible asset divestiture for the three months ended June 30, 2009.

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at  For further information about Altrazeal®, please visit our website at

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the anticipated benefits of our marketing strategy being realized in the second half of 2010, the hiring of additional sales representatives, and the establishment of future business partnerships.  When used in this press release, the words "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the regulatory results for our products.  These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.   These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and other reports filed by us with the Securities and Exchange Commission.ULURU Inc.SUMMARY OF RESULTSSTATEMENTS OF OPERATIONS DATAThree Months Ended June 30,
(Unaudited)Six Months Ended June 30,
(Unaudited)2010200920102009REVENUESLicense fees

$   123,530$   24,925$  145,913$  49,576Royalty income

56,30863,858109,369143,103Product sales


---------32,190Total Revenues

231,634136,094466,864304,823COSTS AND EXPENSESCost of goods sold

6,1618,921136,84414,998Research and development

367,395854,460653,1791,629,879Selling, general and administrative

922,0291,835,4871,738,9174,060,106Amortization of intangible assets


49,99047,00799,98079,578Total Costs and Expenses

1,591,8573,015,0583,121,7186,320,010OPERATING (LOSS)(1,360,223)( 2,878,964)(2,654,854)(6,015,187)Other Income (Expense)Interest and miscellaneous income

59421,06671535,620Interest expense

(8,500)---(16,488)---Loss on sale of intangible asset

(857,839)---(857,839)---Loss on sale of equipment

---(2,121)---(2,121)(LOSS) BEFORE INCOME TAXES( 2,225,968)( 2,860,019)(3,528,466)(5,981,688)Income taxes

------------NET (LOSS)$(2,225,968)$(2,860,019)$ (3,528,466)$ (5,981,688)Basic and diluted net (loss) per common share


81,974,80565,602,99080,970,93165,564,354ULURU Inc.SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATAJune 30, 2010December 31, 2009(Unaudited)(Audited)  Cash and cash equivalents

,934,177  Current assets

3,568,8443,544,850  Property and equipment, net

1,531,5771,631,557  Other assets

6,058,0828,203,965  Total assets

11,158,50313,380,372  Current liabilities

962,517929,771  Long term liabilities – deferred revenue

1,447,2351,272,843  Total liabilities

2,409,7522,202,614  Total stockholders' equity

8,748,75111,177,758Contact: CompanyKerry P. GrayPresident & CEOTerry K. WallbergVice President & CFO(214) 905-5145

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... Nov. 24, 2015  Natera, Inc. (Nasdaq: ... genetic testing and the analysis of circulating ... present at the 27 th  Annual Piper ... 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of ... business activities and financial outlook. ...
(Date:11/24/2015)... , 24. November 2015 Avery ... Pacemaker Systems, ist erfreut, die Berufung von ... bekannt geben zu können. ... --> Foto - ... (Schweden). Von 1984-1986 war er Fellow des ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also ... many people who find their cholesterol levels and weight are creeping up are more ... they don’t have any of the other symptoms. , Thyroid hormone plays a major ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... lower prices in an early celebration of the early holiday shopping season. Starting ... $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition to ...
(Date:11/24/2015)... Mississauga, ON (PRWEB) , ... November 24, 2015 , ... ... Deborah Williams without a referral for dental implants at her Mississauga, ON ... qualified and experienced in the placement of dental implants. , Missing teeth can ...
Breaking Medicine News(10 mins):